Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).
The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access basis for a group of 10 patients.
This news follows a previous announcement (June 15) that CannEpil was added to Ireland’s Primary Care Reimbursement Service, meaning that all Irish patients have the full cost of CannEpil prescriptions covered by the health service.